AMG 176, an MCL-1 inhibitor that exhibited anti-tumor activity against DLBCL and other hematological malignances in vitro [236], has entered the Phase I study in combination with Venetoclax (NCT03797261). Here, MCL1 is linked to diffuse large B-cell lymphoma.